Mackay, Alexander J.
Kostikas, Konstantinos
Roche, Nicolas
Frent, Stefan-Marian
Olsson, Petter
Pfister, Pascal
Gupta, Pritam
Patalano, Francesco
Banerji, Donald
Wedzicha, Jadwiga A.
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 12 December 2019
Accepted: 3 April 2020
First Online: 22 April 2020
Ethics approval
: The FLAME study protocol and all amendments were reviewed by an Independent Ethics Committee or Institutional Review Board for each centre in each country (Japan, Korea, Latvia, Lithuania, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom, Thailand, Croatia, Serbia, Argentina, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Italy). The study was conducted as per the guidelines in the Declaration of Helsinki and Good Clinical Practice guidelines.
: AJM and SMF were ERS fellows with Novartis Pharma AG during this work. AJM is now an employee of AstraZeneca. KK, PP and FP are employees and shareholders of Novartis Pharma AG, and DB is employees and shareholders of Novartis Pharmaceutical Corporation. PG is an employee of Novartis Healthcare Pvt. Ltd. PO is an employee of Novartis AB and shareholder of Novartis Pharma AG. NR reports grants from Boehringer Ingelheim, Pfizer and Novartis, and personal fees from Boehringer Ingelheim, Novartis, Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Pfizer, Sanofi, Sandoz, 3 M, Zambon. JAW reports grants from GSK, Johnson and Johnson, Novartis, Boehringer Ingelheim, AstraZeneca and Chiesi, outside the submitted work.